[
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2003, investigated CC-5013 plus dexamethasone for multiple myeloma, and recruited patients across sites in the United States?",
    "answer": "NCT00056160"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2008, investigated exenatide once weekly, sitagliptin, and pioglitazone for Type 2 Diabetes Mellitus, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00637273"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2005, investigated ecallantide versus Phosphate Buffer Saline for hereditary angioedema, and was conducted in Wheaton, United States?",
    "answer": "NCT00262080"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in March 2007, investigated mannitol compared with placebo for cystic fibrosis, and was conducted across sites in Australia?",
    "answer": "NCT00446680"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2004, compared prasugrel with clopidogrel for coronary arteriosclerosis and acute coronary syndromes, and was conducted in Indianapolis, United States?",
    "answer": "NCT00097591"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 4 interventional study that started in April 1998, investigated atorvastatin for cardiovascular disease, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00327691"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in February 2005, investigated TDF and ADV for chronic hepatitis B, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00117676"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2004, investigated pixantrone with cyclophosphamide and vincristine for non-Hodgkin lymphoma, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00088530"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in March 2008, investigated Pegylated Interferon Alfa 2a, Telaprevir, and Ribavirin for Hepatitis C, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00627926"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2006, investigated pirfenidone compared with placebo for idiopathic pulmonary fibrosis, and recruited patients in Brisbane, United States?",
    "answer": "NCT00287729"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2006, investigated rivaroxaban compared to warfarin for atrial fibrillation and stroke, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00403767"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in April 2006, investigated ipilimumab for melanoma, and was conducted at multiple sites in the United States?",
    "answer": "NCT00289640"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2000, investigated sipuleucel-T compared with APC-Placebo for hormone-refractory prostate cancer, with no locations listed?",
    "answer": "NCT01133704"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2001, investigated filgrastim, oblimersen sodium, and cyclophosphamide for leukemia, and was conducted in Berkeley Heights, United States?",
    "answer": "NCT00024440"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in August 2007, compared alemtuzumab with interferon beta-1a for relapsing-remitting multiple sclerosis, and was conducted across multiple sites in the United States?",
    "answer": "NCT00530348"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2005, investigated Cladribine at two dosages compared with placebo for relapsing-remitting multiple sclerosis?",
    "answer": "NCT00213135"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in November 2005, investigated pazopanib for soft tissue sarcoma, and was conducted in Belgium and France?",
    "answer": "NCT00297258"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2006, investigated lorcaserin 10 mg BID versus placebo for obesity, and was conducted in San Diego, United States?",
    "answer": "NCT00395135"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in February 2005, investigated Certolizumab pegol for rheumatoid arthritis, and was conducted at multiple sites in the United States?",
    "answer": "NCT00152386"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2005, investigated rifaximin compared with placebo for hepatic encephalopathy, and had no locations listed?",
    "answer": "NCT00298038"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2006, investigated bevacizumab, placebo, and erlotinib HCl for non-small cell lung cancer, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00257608"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in October 2006, compared ticagrelor with clopidogrel for acute coronary syndrome, and was conducted across multiple sites in the United States?",
    "answer": "NCT00391872"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in August 2006, investigated Pralatrexate Injection for Peripheral T-cell Lymphoma, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00364923"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in June 2006, investigated eliglustat tartrate for Gaucher Disease, and recruited patients in the United States and Argentina?",
    "answer": "NCT00358150"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a recruiting Phase 1/2 interventional study that started in June 2022, investigated Bexmarilimab with Azacitidine and Venetoclax for acute myeloid leukemia and related conditions, and is conducted in the United States and Finland?",
    "answer": "NCT05428969"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 1/2 interventional study that started in August 2005, investigated tgAAC94 gene therapy vector for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and was conducted across multiple sites in the United States?",
    "answer": "NCT00126724"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in September 2007, investigated carfilzomib for multiple myeloma, and recruited patients across sites in the United States?",
    "answer": "NCT00530816"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2006, compared Fingolimod at two doses with Interferon Î²-1a for multiple sclerosis, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00340834"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in July 2005, investigated cetuximab and oxaliplatin for neoplasm metastasis and colorectal cancer, and was conducted in Austria?",
    "answer": "NCT00125034"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2006, investigated fingolimod versus placebo for multiple sclerosis, and recruited participants across various sites in the United States?",
    "answer": "NCT00355134"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2006, investigated pirfenidone compared with placebo for idiopathic pulmonary fibrosis, and recruited patients in Brisbane, United States?",
    "answer": "NCT00287716"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in August 2003, investigated Angiomax (bivalirudin) for unstable angina and myocardial infarction, and was conducted in New York, United States?",
    "answer": "NCT00093158"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2007, investigated VI-0521 compared with placebo for obesity, and was conducted across multiple sites in the United States?",
    "answer": "NCT00554216"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in August 2005, investigated lenalidomide for non-Hodgkins lymphoma, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00179660"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 1994, investigated adrenergic beta antagonists for heart failure and cardiovascular diseases, with no specific locations listed?",
    "answer": "NCT00000560"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2004, investigated bortezomib for multiple myeloma, and recruited patients in Indianapolis, United States?",
    "answer": "NCT00111319"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in September 2004, investigated teriflunomide compared with placebo for multiple sclerosis, and recruited patients in countries including the United States, Austria, and Canada?",
    "answer": "NCT00134563"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2008, investigated MAP0004 compared with placebo for migraine disorders, and was conducted in Seattle, United States?",
    "answer": "NCT00623636"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in August 2006, investigated panitumumab with the FOLFOX regimen for metastatic colorectal cancer, and had no locations listed?",
    "answer": "NCT00364013"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2003, investigated Sipuleucel-T versus APC-Placebo for prostate cancer, and was conducted at multiple sites in the United States?",
    "answer": "NCT00065442"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for an active, not recruiting Phase 3 interventional study that started in November 2012, investigated brentuximab vedotin with other drugs for Hodgkin Lymphoma, and took place in multiple locations across the United States?",
    "answer": "NCT01712490"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2005, investigated Naproxcinod 375 mg and Naproxen for osteoarthritis, with no locations listed?",
    "answer": "NCT00542555"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2007, investigated Naltrexone SR 32 mg/bupropion SR 360 mg/day with placebo for obesity and overweight, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00567255"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in September 2006, compared Eribulin Mesylate with Capecitabine for metastatic breast cancer, and was conducted across multiple sites in the United States?",
    "answer": "NCT00337103"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2006, investigated pegloticase versus placebo for gout, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00325195"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in August 2007, investigated carfilzomib for multiple myeloma, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00511238"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in December 2005, investigated ipilimumab with placebo or budesonide for malignant melanoma, and recruited patients in the United States and Canada?",
    "answer": "NCT00135408"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a terminated Phase 3 interventional study that started in February 2006, investigated liraglutide and glimepiride for Type 2 Diabetes, and was conducted at multiple sites in the United States?",
    "answer": "NCT00294723"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2003, investigated azacitidine versus physician choice for myelodysplastic syndromes, and was conducted across multiple sites in the United States?",
    "answer": "NCT00071799"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in June 2006, investigated lenalidomide for non-Hodgkin's lymphoma, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00413036"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2016, investigated filgotinib with placebo for rheumatoid arthritis, and was conducted at multiple sites in the United States?",
    "answer": "NCT02873936"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2010, investigated LI, cyclophosphamide, and indomethacin for squamous cell carcinoma of the oral cavity and soft palate, and recruited patients across multiple sites in the United States?",
    "answer": "NCT01265849"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2004, investigated terlipressin versus placebo for hepatorenal syndrome, and was conducted at multiple sites in the United States?",
    "answer": "NCT00089570"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in October 2003, investigated Toremifene Citrate for prostate cancer, osteoporosis, and fractures, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00129142"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in March 2006, investigated docetaxel with bevacizumab or placebo for breast cancer, and was conducted in multiple locations in Australia?",
    "answer": "NCT00333775"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2006, compared warfarin with apixaban for atrial fibrillation and atrial flutter, and recruited patients in multiple locations across the United States?",
    "answer": "NCT00412984"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2008, investigated lorcaserin at different dosages compared to placebo for obesity, and was conducted in San Diego, United States?",
    "answer": "NCT00603902"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2004, investigated cetuximab with FOLFIRI for EGFR-expressing metastatic colorectal cancer, and recruited patients in Argentina and Australia?",
    "answer": "NCT00154102"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2006, investigated Denosumab and Zoledronic Acid for bone metastases?",
    "answer": "NCT00321464"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in October 2007, investigated Naltrexone SR and Bupropion SR for obesity and overweight, and was conducted across multiple sites in the United States?",
    "answer": "NCT00532779"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2006, investigated denufosol tetrasodium inhalation solution compared with placebo for cystic fibrosis?",
    "answer": "NCT00357279"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2007, investigated dextromethorphan hydrobromide with quinidine sulfate for Pseudobulbar Affect, and was conducted across multiple sites in the United States?",
    "answer": "NCT00573443"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for an active, not recruiting Phase 2/3 interventional study that started in September 2018, investigated RGX-121 for Mucopolysaccharidosis Type II, and recruited patients in the United States and Brazil?",
    "answer": "NCT03566043"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 1/2 interventional study that started in April 2006, investigated SB-743921 for Non-Hodgkin's Lymphoma and Hodgkin's Disease, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00343564"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2001, investigated natalizumab versus placebo for relapsing-remitting multiple sclerosis, and was conducted at multiple sites in the United States?",
    "answer": "NCT00027300"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 2005, compared warfarin with two doses of Dabigatran for atrial fibrillation and stroke, and recruited patients in the United States?",
    "answer": "NCT00262600"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in December 1998, investigated Ampligen for chronic fatigue syndrome and myalgic encephalomyelitis, with no locations listed?",
    "answer": "NCT00215800"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in August 2000, investigated Tecemotide with cyclophosphamide and best supportive care for non-small-cell lung carcinoma, and was conducted in Darmstadt, Germany?",
    "answer": "NCT00157209"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2008, compared exenatide once weekly with insulin glargine for Type 2 Diabetes Mellitus, and was conducted across multiple sites in the United States?",
    "answer": "NCT00641056"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2005, investigated Ustekinumab for psoriasis, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00307437"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2017, investigated LentiGlobin BB305 Drug Product for beta-thalassemia, and recruited patients in the United States, France, and Germany?",
    "answer": "NCT03207009"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2004, investigated bendamustine versus standard chemotherapy CHOP plus rituximab for various lymphomas, and was conducted in Giessen, Germany?",
    "answer": "NCT00991211"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in December 2002, investigated Interferon beta-1a and Alemtuzumab for relapsing-remitting multiple sclerosis, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00050778"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2006, investigated Fingolimod at two dosages compared with placebo for relapsing-remitting multiple sclerosis, and included sites in Australia?",
    "answer": "NCT00289978"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in October 2004, investigated ranolazine versus placebo for myocardial ischemia, and was conducted in Boston, United States?",
    "answer": "NCT00099788"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2005, investigated trabectedin with DOXIL and dexamethasone for ovarian cancer, and was conducted across multiple sites in the United States?",
    "answer": "NCT00113607"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2005, investigated TDF and ADV for chronic hepatitis B, and was conducted across multiple sites in the United States?",
    "answer": "NCT00116805"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2007, investigated laquinimod versus placebo for multiple sclerosis, and was conducted at sites in the United States?",
    "answer": "NCT00509145"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in May 2007, investigated GTx-024 compared with placebo for cachexia, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00467844"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in August 2007, compared liraglutide with exenatide for Type 2 Diabetes, and was conducted across multiple sites in the United States?",
    "answer": "NCT00518882"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2007, investigated BG00012 compared with placebo for relapsing-remitting multiple sclerosis, and was conducted across multiple sites in the United States?",
    "answer": "NCT00420212"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 1997, investigated Docetaxel, 5-fluorouracil, and Doxorubicin for breast cancer, and recruited patients in countries including the United States, Argentina, and Canada?",
    "answer": "NCT00688740"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 1/2 interventional study that started in March 2007, investigated MYDICAR with placebo for heart failure and dilated cardiomyopathy, and recruited patients across sites in the United States?",
    "answer": "NCT00454818"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in April 2006, investigated long-acting release exenatide for Type 2 Diabetes Mellitus, and was conducted at multiple sites in the United States?",
    "answer": "NCT00308139"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2007, investigated BG00012, placebo, and glatiramer acetate for relapsing-remitting multiple sclerosis, and recruited patients across sites in the United States?",
    "answer": "NCT00451451"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2006, investigated fidaxomicin versus vancomycin for Clostridium infections and diarrhea?",
    "answer": "NCT00314951"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a terminated Phase 2 interventional study that started in January 2006, investigated belinostat for various lymphomas, and was conducted at multiple sites in the United States?",
    "answer": "NCT00274651"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in January 2007, investigated GP2 peptide plus GM-CSF vaccine for breast cancer, and recruited patients in multiple locations across the United States?",
    "answer": "NCT00524277"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in January 2003, investigated CC-5013 plus dexamethasone for multiple myeloma, and recruited patients across multiple sites in Australia?",
    "answer": "NCT00424047"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in October 2006, compared PAR-101/OPT-80 with Vancomycin for Clostridium infections and diarrhea, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00468728"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in May 2006, investigated liraglutide, metformin, and glimepiride for Type 2 Diabetes, and included sites in Argentina and Australia?",
    "answer": "NCT00318461"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in March 1998, compared letrozole with tamoxifen citrate for breast cancer, and was conducted in Denmark, France, and Switzerland?",
    "answer": "NCT00004205"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2006, investigated panitumumab with FOLFIRI for metastatic colorectal cancer, and had no locations listed?",
    "answer": "NCT00339183"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in July 2007, compared nilotinib with imatinib for chronic myelogenous leukemia, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00471497"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in October 2003, investigated Belimumab at different dosages compared with placebo for systemic lupus erythematosus, and was conducted across multiple sites in the United States?",
    "answer": "NCT00071487"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in September 2007, investigated PV-10 (10% rose bengal disodium) for melanoma, and recruited patients in the United States and Australia?",
    "answer": "NCT00521053"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in June 2005, investigated TH9507 for HIV infections and lipodystrophy, and recruited patients in multiple locations across California, United States?",
    "answer": "NCT00123253"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 1999, investigated sipuleucel-T compared with placebo for prostate cancer, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00005947"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 2 interventional study that started in December 2007, investigated Sapacitabine for acute myeloid leukemia, and was conducted across multiple sites in the United States?",
    "answer": "NCT00590187"
  },
  {
    "question": "In ClinicalTrials.gov, what is the NCT number for a completed Phase 3 interventional study that started in November 2007, investigated VI-0521 for obesity and type 2 diabetes, and recruited patients across multiple sites in the United States?",
    "answer": "NCT00553787"
  }
]